Preclinical and early clinical findings suggest that cannabinoids—particularly CBD—and enzymatic inhibitors of the endocannabinoid system, such as FAAH and MAGL inhibitors, hold significant therapeutic potential for anxiety and depressive disorders. This evidence concerns the gene FAAH and Anxiety.